Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2013
05/08/2013EP2588474A2 Process for the preparation of hmg-coa reductase inhibitors and intermediates thereof
05/08/2013EP2588473A1 Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
05/08/2013EP2588471A1 Heterocyclic compounds and their use as inhibitors of pi3k activity
05/08/2013EP2588470A1 Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
05/08/2013EP2588469A1 Heterocyclic compounds and their use as inhibitors of pi3k activity
05/08/2013EP2588468A1 Heterocyclic compounds and their use as inhibitors of pi3k activity
05/08/2013EP2588466A1 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
05/08/2013EP2588465A1 Sgc stimulators
05/08/2013EP2588464A1 Benzofuran derivatives for the treatment of hepatits c
05/08/2013EP2588463A1 Metronidazole esters for treating rosacea
05/08/2013EP2588462A1 Metronidazole esters for treating rosacea
05/08/2013EP2588461A1 Metronidazole esters for treating rosacea
05/08/2013EP2588459A1 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
05/08/2013EP2588458A1 Novel tetrahydroquinoline derivatives
05/08/2013EP2588457A1 Pyrazolo-quinolines
05/08/2013EP2588455A1 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
05/08/2013EP2588454A1 Substituted dicyanopyridines and use thereof
05/08/2013EP2588453A1 Compositions and methods for modulating the wnt signaling pathway
05/08/2013EP2588447A1 Novel salts as anti-inflammatory, immunomodulatory and anti-proliferatory agents
05/08/2013EP2588446A1 Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents
05/08/2013EP2588445A1 New polymorphic form of a calcimimetic compound
05/08/2013EP2588444A1 New polymorphic form of a calcimimetic compound
05/08/2013EP2588198A1 Treatment of cognitive disorders
05/08/2013EP2588197A1 Fused heterocyclic compounds as ion channel modulators
05/08/2013EP2588146A1 L-methylfolate treatment for psychiatric or neurologic disorders
05/08/2013EP2588129A2 Small-molecule-targeted protein degradation
05/08/2013EP2588125A2 Functional vascularization with biocompatible polysaccharide-based hydrogels
05/08/2013EP2588124A1 Single-walled carbon nanotube/sirna complexes and methods related thereto
05/08/2013EP2588119A2 Methods and compositions for enhancing stem cell mobilization
05/08/2013EP2588117A1 Stable antiseptic compositions and methods
05/08/2013EP2588116A1 Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
05/08/2013EP2588115A1 Aptamers that inhibit interaction between antibody and 2nd extracellular loop of human beta-1-adrenergic receptor
05/08/2013EP2588114A1 Pharmaceutical composition comprising drospirenone and contraceptive kit
05/08/2013EP2588113A1 A reconstituted high density lipoprotein formulation and production method thereof
05/08/2013EP2588112A2 Methods and compositions for treatment of multiple sclerosis
05/08/2013EP2588111A1 Statin therapy monitored by galectin- 3 measurement
05/08/2013EP2588110A1 Methods of targeting pten mutant diseases and compositions therefor
05/08/2013EP2588109A1 Use of kynurenic acid amide derivatives for the treatment of huntington's disease
05/08/2013EP2588108A2 Treatment for dyslipidemia
05/08/2013EP2588107A1 COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
05/08/2013EP2588106A2 Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability
05/08/2013EP2588105A1 Triazolopyridines as tyk2 inhibitors
05/08/2013EP2588104A1 Isoindolone m1 receptor positive allosteric modulators
05/08/2013EP2588103A1 A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases
05/08/2013EP2588102A1 New dosage forms for treatment of cardiovascular diseases
05/08/2013EP2588101A1 N-acyl amino acid derivatives for treating skin conditions such as cellulite
05/08/2013EP2588100A1 Topical pharmaceutical composition comprising flurbiprofen
05/08/2013EP2588099A2 Methods of treating restless legs syndrome
05/08/2013EP2588098A1 Compounds for the treatment of posterior segment disorders and diseases
05/08/2013EP2588097A2 Pharmaceutical compositions comprising paracetamol and process for preparing the same
05/08/2013EP2588096A1 Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
05/08/2013EP2588095A1 Composition for the treatment of acne vulgaris
05/08/2013EP2588094A2 Pharmaceutical compositions for sublingual delivery of opioids
05/08/2013EP2588093A1 Tapentadol for use in the treatment of irritable bowel syndrome
05/08/2013EP2588092A1 Use of squaramide in the prevention and/or treatment of rosacea
05/08/2013EP2588089A1 Micro particles for oral delivery in animals
05/08/2013EP2588087A2 Compositions with a high active ingredient fraction of pharmaceutically active substances
05/08/2013EP2588086A2 Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.
05/08/2013EP2588085A1 Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
05/08/2013EP2588084A1 Antibiotic compositions
05/08/2013EP2588078A1 Polymeric system for delivering a preservative-free prostaglandin-based nonviscous solution
05/08/2013EP2588049A2 Ophthalmic devices containing chemokine antagonists
05/08/2013EP2587920A1 Antimicrobial combinations of pyrion compounds with polyethyleneimines
05/08/2013EP2587919A1 Methods for treating post traumatic stress disorder
05/08/2013EP2587917A1 Anti-fibroblastic fluorochemical emulsion therapies
05/08/2013EP2340851A9 Diagnosis method and therapeutic method for cancer
05/08/2013DE102011117874A1 New dimethyl sulfoxide solvate hydrate of erythromycin useful for combating germs e.g. Bacillus anthracis and Streptococcus and treating lower respiratory tract disorder e.g. bronchitis, pneumonia and whooping cough
05/08/2013DE102011117839A1 Herstellung von Hydrogelen mittels Diels-Alder Reaktion Preparation of hydrogels by Diels-Alder reaction
05/08/2013DE102011117634A1 Formulation for treating intestinal infections with extended-spectrum beta-lactamase -bacteria, preferably resistant Gram-negative bacteria, e.g. Klebsiella, and beta-lactamases forming germs, comprises iodochlorohydroxyquinoline
05/08/2013DE102011085798A1 Synergistisch wirksame ternäre antimikrobielle Mischungen Synergistically active ternary mixtures antimicrobial
05/08/2013DE102011085695A1 Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten Once oxazaphosphorines dose for the treatment of diseases
05/08/2013CN202920809U Ointment for treating condyloma acuminata
05/08/2013CN202920665U Musk bone-strengthening paste
05/08/2013CN1732944B Entecavir dispersible tablet and its preparation process
05/08/2013CN103097535A Method for producing novel hipsc by means of sirna introduction
05/08/2013CN103097534A Double stranded RNA compounds to RHOA and use thereof
05/08/2013CN103097396A 6-substituted demethyl-estradiol derivatives as er-beta agonists
05/08/2013CN103097393A Quinoxaline compound
05/08/2013CN103097392A Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring
05/08/2013CN103097391A Novel spiroheterocyclic compounds as mGlu5 antagonists
05/08/2013CN103097390A Application of beta-functionalized dihydroxy-chlorins for PDT
05/08/2013CN103097389A 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace)
05/08/2013CN103097388A New aminopyrazoloquinazolines
05/08/2013CN103097387A Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
05/08/2013CN103097386A Lipidated immune response modifier compound compositions, formulations, and methods
05/08/2013CN103097385A Ip receptor agonist heterocyclic compounds
05/08/2013CN103097384A Substituted imidazo[1,2-a]pyrimidines and pyridines
05/08/2013CN103097383A Pyrazoloquinoline compound
05/08/2013CN103097382A 2-(arylamino)-3H-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as MPGES-1 inhibitors
05/08/2013CN103097381A 1, 8-naphthyridines as kinase inhibitors
05/08/2013CN103097380A Inhibitor of casein kinase 1[delta] and casein kinase 1[epsilon]
05/08/2013CN103097379A Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
05/08/2013CN103097377A New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl) thio]-6{[(1r,2s)-2,3-dihydroxy-1-methylpropyl]oxy} 4-pyrimidinyl]-1-azetidinesulfonamide
05/08/2013CN103097375A Cyclohexyl-azetidinyl antagonists of CCR2
05/08/2013CN103097374A Metalloenzyme inhibitor compounds
05/08/2013CN103097373A Pro-drugs of (e) -7- (3- (2-amino-1-fluoroethylidene) piperidin-1-yl) -1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
05/08/2013CN103097370A Benzofuran derivatives for the treatment of hepatits c
05/08/2013CN103097368A Tricyclic lactones for treatment of cancer
05/08/2013CN103097365A 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (S1P) receptors
05/08/2013CN103097364A Spiro-Cyclic Amine Derivatives as S1P Modulators
1 ... 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 ... 7860